Business
Aelis Farma: Availability of the 2024 Universal Registration Document
BORDEAUX, France, April 29, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2024 Universal Registration Document (URD) as filed with the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 28, 2025, under number D.25-0314.
About this update from Aelis Farma Sa
[{"type":"text","content":"BORDEAUX, France, April 29, 2025--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2024 Universal Registration Document (URD) as filed with the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 28, 2025, under number D.25-0314.","length":418,"tagName":"p"},{"type":"text","content":"The Universal Registration Document 2024 includes in particular:","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The 2024 annual financial report;","length":33,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The statutory auditor’s reports;","length":32,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Information on the statutory auditor’s fees;","length":44,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Information relating to corporate social responsibility.","length":56,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":165,"olType":false},{"type":"text","content":"The URD can be consulted and downloaded on the Company’s website under the heading Investors / Documentation, as well as on the AMF website (https://www.amf-france.org).","length":169,"tagName":"p"},{"type":"text","content":"Financial Agenda:","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Annual General Meeting, May 27, 2025","length":36,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"2025 Half-Year Results, September 22, 2025","length":42,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":78,"olType":false},{"type":"text","content":"***","length":3,"tagName":"p","attribs":{}},{"type":"text","content":"About AELIS FARMA","length":17,"tagName":"p"},{"type":"text","content":"Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity...